Eli Lilly & Co. (NYSE:LLY)

Big Pharma Short Sellers Hike Their Bets

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Big Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Eli Lilly Just Couldn’t Get It Together in Q3

When Eli Lilly and Co. (NYSE: LLY) released its third-quarter financial results before the markets opened on Wednesday, the pharmaceutical giant said that it had $1.48 in earnings per share ...
Read Full Story »

How Biotech and Big Pharma Have Upside Heading Into Earnings

Biotech and many of the so-called Big Pharma have been duds in 2019. Despite many FDA approvals and some powerful mergers and royalty deals, the political pressure around drug pricing ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Abbott Labs, CSX, IBM, Netflix, Occidental, Whiting, Amgen, Gilead, Merck, Pfizer and More

Stocks were indicated to open marginally higher on Thursday as the world appears to have better hopes for a Brexit framework out of Europe. Investors are having to grapple with ...
Read Full Story »

Big Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Plaque Psoriasis Suffers May Have Better Option After Eli Lilly Study

Eli Lilly and Co. (NYSE: LLY) announced some good news for people suffering moderate to severe plaque psoriasis when it presented at the Fifth Annual Maui Derm NP+PA Fall meeting. ...
Read Full Story »

Why Dividend-Paying Large-Cap Pharmaceuticals Could Shine in Q4

With the final quarter of 2019 beginning next Tuesday, many investors are taking a long hard look at their portfolios and trying to make some adjustments. While the end of ...
Read Full Story »

Short Sellers Grow More Selective in Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Surprising Reaction to Lung Cancer Study Results

After Eli Lilly and Co. (NYSE: LLY) announced results from its midstage clinical trial for the treatment of lung cancer, its shares dipped on Monday. Specifically, these results come from ...
Read Full Story »

Is NextCure the Next Big Cancer Biotech Every Investor Missed?

The initial public offering class of 2018 and 2019 has been very mixed. There have been some great winners, but there also have been some very well-known unicorns that have ...
Read Full Story »

Big Pharma Sees a Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Huge Plaque Psoriasis Breakthrough at Eli Lilly

Eli Lilly and Co. (NYSE: LLY) shares made a handy gain on Tuesday after the firm announced results from its late-stage study for the treatment of moderate to severe plaque ...
Read Full Story »